Atrial Appendage Articles & Analysis
12 news found
Like many people with atrial fibrillation (AFib), Sheldon Kittelson of Clarkfield, Minnesota, felt trapped between the fear of having a stroke and the fear of spending a lifetime on blood thinners. For people with AFib, blood doesn’t flow through the heart normally, which can result in a clot forming in the left atrial appendage ...
Earlier this year, physicians at Montreal Heart Institute used the Biomodex® LAACS™ (Left Atrial Appendage Closure System) simulator to rehearse the full procedure of a Left Atrial Appendage Occlusion (LAAO). ...
ByBIOMODEX
(Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. ...
(Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced second quarter 2021 financial results. ...
(Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference. ...
BIOMODEX, the leader in bio-realistic haptic simulators for patient-specific rehearsal and physician training, today announced that its LAACS (Left Atrial Appendage Closure System) solution was used to perform a simulation ahead of a live case to be presented at the TVT Structural Heart Summit in Miami, FL. Physicians at the Montreal Heart Institute in Montreal, ...
ByBIOMODEX
(Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Deborah H. ...
(Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced U.S. ...
SANTA CLARA, Calif., July 16, 2020 -- Cardiva Medical, Inc., an innovator in the field of vascular closure, today announced the first patient enrollments in its AMBULATE Same Day Discharge study, the first prospective multi-center study designed to evaluate same-day discharge for patients undergoing cardiac ablation procedures for atrial fibrillation. The study is utilizing the ...
We are thrilled with the reception from physicians, and with the results we are seeing with this technology to help patients get back on their feet faster after procedures such as cardiac ablation and left atrial appendage closure.” The AMBULATE pivotal study is a randomized, controlled study of 204 patients across 13 sites treated with the VASCADE MVP ...
Potential procedures include cardiac ablation and left atrial appendage closure among others. Greater than 400,000 patients per year in the United States may benefit – with procedures growing double digits each year. ...
On November 28, 2016, Amsel Medical Corporation announced Presentation of “A Novel Mechanical Closure Device for Left Atrial Appendage Orifice and Closure of Right Atrial Incision” at the International Conference for Innovations in Cardiovascular Systems (ICI) Meeting 2016, Israel. ...